Biology Reference
In-Depth Information
73. Lapchak PA (2010) Erythropoietin molecules
to treat acute ischemic stroke: a translational
dilemma! Expert Opin Investig Drugs
19:1179-1186
74. Montero M et al (2007) Comparison of neuro-
protective effects of erythropoietin (EPO) and
carbamylerythropoietin (CEPO) against isch-
emia-like oxygen-glucose deprivation (OGD)
and NMDA excitotoxicity in mouse hippocam-
pal slice cultures. Exp Neurol 204:106-117
75. Doggrell SA (2004) A neuroprotective
derivative of erythropoietin that is not
erythropoietic. Expert Opin Investig Drugs
13:1517-1519
76. Yamashita T et al (2010) Asialoerythropoietin
attenuates neuronal cell death in the hippocam-
pal CA1 region after transient forebrain ischemia
in a gerbil model. Neurol Res 32:957-962
77. Price CD et al (2010) Effect of continuous
infusion of asialoerythropoietin on short-term
changes in infarct volume, penumbra apopto-
sis and behaviour following middle cerebral
artery occlusion in rats. Clin Exp Pharmacol
Physiol 37:185-192
78. Gan Y et al (2012) Mutant erythropoietin
without erythropoietic activity is neuroprotec-
tive against ischemic brain injury. Stroke 43:
3071-3077
79. Fletcher L et al (2009) Intranasal delivery of
erythropoietin plus insulin-like growth factor-I
for acute neuroprotection in stroke. Laboratory
investigation. J Neurosurg 111:164-170
80. Yu YP et al (2005) Intranasal recombinant
human erythropoietin protects rats against
focal cerebral ischemia. Neuro sci Lett 387:
5-10
81. Aluclu MU et al (2007) Evaluation of erythro-
poietin effects on cerebral ischemia in rats.
Neuro Endocrinol Lett 28:170-174
82. Sadamoto Y et al (1998) Erythropoietin pre-
vents place navigation disability and cortical
infarction in rats with permanent occlusion of
the middle cerebral artery. Biochem Biophys
Res Commun 253:26-32
83. Villa P et al (2007) Reduced functional deficits,
neuroinflammation, and secondary tissue dam-
age after treatment of stroke by nonerythro-
poietic erythropoietin derivatives.
J Cereb Blood Flow Metab 27:552-563
84. Li Y et al (2007) Erythropoietin-induced
neurovascular protection, angiogenesis, and
cerebral blood flow restoration after focal isch-
emia in mice. J Cereb Blood Flow Metab 27:
1043-1054
85. Li L et al (2009) MRI identification of white
matter reorganization enhanced by erythro-
poietin treatment in a rat model of focal isch-
emia. Stroke 40:936-941
86. Ding G et al (2010) Cerebral tissue repair and
atrophy after embolic stroke in rat: a magnetic
resonance imaging study of erythropoietin
therapy. J Neuro sci Res 88(14):3206-3214
87. Wakida K et al (2007) Neuroprotective effect
of erythropoietin, and role of metallothionein-1
and -2, in permanent focal cerebral ischemia.
Neuro sci 148:105-114
88. Fu A et al (2010) Neuroprotection in experi-
mental stroke in the rat with an IgG-
erythropoietin fusion protein. Brain Res
1360:193-197
89. Leist M et al (2004) Derivatives of erythropoi-
etin that are tissue protective but not erythro-
poietic. Science 305:239-242
90. Belayev L et al (2005) Neuroprotective effect
of darbepoetin alfa, a novel recombinant
erythropoietic protein, in focal cerebral isch-
emia in rats. Stroke 36:1071-1076
91. Wang Y et al (2007) Post-ischemic treatment
with erythropoietin or carbamylated eryth-
ropoietin reduces infarction and improves
neurological outcome in a rat model of focal
cerebral ischemia. Br J Pharmacol 151:
1377-1384
92. Fu A et al (2011) Neuroprotection in stroke in
the mouse with intravenous erythropoietin-
Trojan horse fusion protein. Brain Res 1369:
203-207
Search WWH ::
Custom Search